Among these, LAG-3 became the third clinically validated checkpoint target, with the recent RELATIVITY-047 (NCT03470922) data resulting in FDA approval of the anti-LAG-3 antibody relatlimab in combination with the anti-PD-1 antibody nivolumab for the treatment of unresectable or metastatic melanoma (3, 4). This evidence concerns the gene LAG3 and metastatic melanoma.